Cargando…

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples

BACKGROUND: The study was conducted to evaluate the feasibility of using malignant pleural effusion (MPE) as a substitute specimen for genetic testing and to determine the significance of genetic profiling of MPE tumor cells to monitor non‐small cell lung cancer (NSCLC) progression and therapeutic r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yi, Peng, Min, Shen, Qinglin, Hu, Qinyong, Gong, Hongyun, Li, Qingqing, Zheng, Zhongliang, Xu, Bin, Li, Yingge, Dong, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360205/ https://www.ncbi.nlm.nih.gov/pubmed/30565433 http://dx.doi.org/10.1111/1759-7714.12932

Ejemplares similares

Detection of ALK Gene Rearrangement in Cell-free RNA from Lung Cancer Malignant Pleural Effusion
por: Chu, Mingliang, et al.
Publicado: (2020)

High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion
por: Yi, Fengshuang, et al.
Publicado: (2019)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples
por: Frankel, Diane, et al.
Publicado: (2022)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Management of Malignant Pleural Effusions
por: Villanueva, Andrew G.
Publicado: (2012)

Management of Malignant Pleural Effusions
por: Charpidou, Adrianni, et al.
Publicado: (2006)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion
por: Acencio, Milena Marques Pagliarelli, et al.
Publicado: (2017)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Management of malignant pleural effusion with different pleural catheters
por: Karapolat, Sami, et al.
Publicado: (2018)

Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion
por: Shan, Yi, et al.
Publicado: (2017)

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma
por: Liu, Dan, et al.
Publicado: (2014)

Malignant pleural effusions: Differentiating pelvic malignancies
por: Sharma, Mukesh, et al.
Publicado: (2015)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India
por: Tarigopula, Anil, et al.
Publicado: (2020)

An Update in the Management of Malignant Pleural Effusion
por: Muduly, DK, et al.
Publicado: (2011)

Ferritin Assay in Malignant Pleural Effusion
por: Chung, Won-Tae, et al.
Publicado: (1987)

Primary malignant myelomatous pleural effusion
por: Mangla, Ankit, et al.
Publicado: (2016)

Pleural procedures in the management of malignant effusions
por: Ferreiro, Lucía, et al.
Publicado: (2017)

Management of Septated Malignant Pleural Effusions
por: Banka, Radhika, et al.
Publicado: (2018)

Malignant Pleural Effusion: Diagnosis and Management
por: Ferreiro, Lucía, et al.
Publicado: (2020)

Surgical treatment in malignant pleural effusion
por: Karadayı, Şule, et al.
Publicado: (2021)

Malignant pleural effusion diagnosis and therapy
por: Yang, Liangliang, et al.
Publicado: (2023)

Clinical identification of malignant pleural effusions
por: Jia, Jianlong, et al.
Publicado: (2023)

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review
por: Zhang, Man, et al.
Publicado: (2021)

Use of Platelet Parameters in the Differential Diagnosis of Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Tuberculous Pleural Effusion
por: Ai, Ling, et al.
Publicado: (2022)

mRNA markers associated with malignant pleural effusion
por: Hsu, Shih-Chang, et al.
Publicado: (2023)

Implantation of permanent pleural catheter for palliation of malignant pleural effusion
por: Meier, Michelle, et al.
Publicado: (2016)

Accuracy of closed pleural biopsy in the diagnosis of malignant pleural effusion
por: Báez-Saldaña, Renata, et al.
Publicado: (2017)

The diagnostic value of pleural fluid homocysteine in malignant pleural effusion
por: Santotoribio, Jose D., et al.
Publicado: (2019)

Indwelling pleural catheters for malignant pleural effusion – Are we ready?
por: Patel, Dharmesh, et al.
Publicado: (2022)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q0bpdmnq4gcj6a0ektm4nkeguc